Plasma free amino acid profiling of five types of cancer patients and its application for early detection

Yohei Miyagi, Masahiko Higashiyama, Akira Gochi, Makoto Akaike, Takashi Ishikawa, Takeshi Miura, Nobuhiro Saruki, Etsuro Bando, Hideki Kimura, Fumio Imamura, Masatoshi Moriyama, Ichiro Ikeda, Akihiko Chiba, Fumihiro Oshita, Akira Imaizumi, Hiroshi Yamamoto, Hiroshi Miyano, Katsuhisa Horimoto, Osamu Tochikubo, Toru MitsushimaMinoru Yamakado, Naoyuki Okamoto

Research output: Contribution to journalArticle

204 Citations (Scopus)

Abstract

Background: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection methods using blood samples. Among metabolites, profiling of plasma free amino acids (PFAAs) is a promising approach because PFAAs link all organ systems and have important roles in metabolism. Furthermore, PFAA profiles are known to be influenced by specific diseases, including cancers. Therefore, the purpose of the present study was to determine the characteristics of the PFAA profiles in cancer patients and the possibility of using this information for early detection. Methods and Findings: Plasma samples were collected from approximately 200 patients from multiple institutes, each diagnosed with one of the following five types of cancer: lung, gastric, colorectal, breast, or prostate cancer. Patients were compared to gender- and age- matched controls also used in this study. The PFAA levels were measured using high-performance liquid chromatography (HPLC)-electrospray ionization (ESI)-mass spectrometry (MS). Univariate analysis revealed significant differences in the PFAA profiles between the controls and the patients with any of the five types of cancer listed above, even those with asymptomatic early-stage disease. Furthermore, multivariate analysis clearly discriminated the cancer patients from the controls in terms of the area under the receiver-operator characteristics curve (AUC of ROC >0.75 for each cancer), regardless of cancer stage. Because this study was designed as case-control study, further investigations, including model construction and validation using cohorts with larger sample sizes, are necessary to determine the usefulness of PFAA profiling. Conclusions: These findings suggest that PFAA profiling has great potential for improving cancer screening and diagnosis and understanding disease pathogenesis. PFAA profiles can also be used to determine various disease diagnoses from a single blood sample, which involves a relatively simple plasma assay and imposes a lower physical burden on subjects when compared to existing screening methods.

Original languageEnglish
Article numbere24143
JournalPLoS One
Volume6
Issue number9
DOIs
Publication statusPublished - 2011

Fingerprint

free amino acids
Plasmas
Amino Acids
neoplasms
Neoplasms
Early Detection of Cancer
screening
Screening
Blood
sampling
operator regions
blood
metabolomics
prostatic neoplasms
disease diagnosis
lung neoplasms
Electrospray ionization
case-control studies
Metabolomics
Electrospray Ionization Mass Spectrometry

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Miyagi, Y., Higashiyama, M., Gochi, A., Akaike, M., Ishikawa, T., Miura, T., ... Okamoto, N. (2011). Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One, 6(9), [e24143]. https://doi.org/10.1371/journal.pone.0024143

Plasma free amino acid profiling of five types of cancer patients and its application for early detection. / Miyagi, Yohei; Higashiyama, Masahiko; Gochi, Akira; Akaike, Makoto; Ishikawa, Takashi; Miura, Takeshi; Saruki, Nobuhiro; Bando, Etsuro; Kimura, Hideki; Imamura, Fumio; Moriyama, Masatoshi; Ikeda, Ichiro; Chiba, Akihiko; Oshita, Fumihiro; Imaizumi, Akira; Yamamoto, Hiroshi; Miyano, Hiroshi; Horimoto, Katsuhisa; Tochikubo, Osamu; Mitsushima, Toru; Yamakado, Minoru; Okamoto, Naoyuki.

In: PLoS One, Vol. 6, No. 9, e24143, 2011.

Research output: Contribution to journalArticle

Miyagi, Y, Higashiyama, M, Gochi, A, Akaike, M, Ishikawa, T, Miura, T, Saruki, N, Bando, E, Kimura, H, Imamura, F, Moriyama, M, Ikeda, I, Chiba, A, Oshita, F, Imaizumi, A, Yamamoto, H, Miyano, H, Horimoto, K, Tochikubo, O, Mitsushima, T, Yamakado, M & Okamoto, N 2011, 'Plasma free amino acid profiling of five types of cancer patients and its application for early detection', PLoS One, vol. 6, no. 9, e24143. https://doi.org/10.1371/journal.pone.0024143
Miyagi, Yohei ; Higashiyama, Masahiko ; Gochi, Akira ; Akaike, Makoto ; Ishikawa, Takashi ; Miura, Takeshi ; Saruki, Nobuhiro ; Bando, Etsuro ; Kimura, Hideki ; Imamura, Fumio ; Moriyama, Masatoshi ; Ikeda, Ichiro ; Chiba, Akihiko ; Oshita, Fumihiro ; Imaizumi, Akira ; Yamamoto, Hiroshi ; Miyano, Hiroshi ; Horimoto, Katsuhisa ; Tochikubo, Osamu ; Mitsushima, Toru ; Yamakado, Minoru ; Okamoto, Naoyuki. / Plasma free amino acid profiling of five types of cancer patients and its application for early detection. In: PLoS One. 2011 ; Vol. 6, No. 9.
@article{1be3b84ba9184050b2391d764e8a700d,
title = "Plasma free amino acid profiling of five types of cancer patients and its application for early detection",
abstract = "Background: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection methods using blood samples. Among metabolites, profiling of plasma free amino acids (PFAAs) is a promising approach because PFAAs link all organ systems and have important roles in metabolism. Furthermore, PFAA profiles are known to be influenced by specific diseases, including cancers. Therefore, the purpose of the present study was to determine the characteristics of the PFAA profiles in cancer patients and the possibility of using this information for early detection. Methods and Findings: Plasma samples were collected from approximately 200 patients from multiple institutes, each diagnosed with one of the following five types of cancer: lung, gastric, colorectal, breast, or prostate cancer. Patients were compared to gender- and age- matched controls also used in this study. The PFAA levels were measured using high-performance liquid chromatography (HPLC)-electrospray ionization (ESI)-mass spectrometry (MS). Univariate analysis revealed significant differences in the PFAA profiles between the controls and the patients with any of the five types of cancer listed above, even those with asymptomatic early-stage disease. Furthermore, multivariate analysis clearly discriminated the cancer patients from the controls in terms of the area under the receiver-operator characteristics curve (AUC of ROC >0.75 for each cancer), regardless of cancer stage. Because this study was designed as case-control study, further investigations, including model construction and validation using cohorts with larger sample sizes, are necessary to determine the usefulness of PFAA profiling. Conclusions: These findings suggest that PFAA profiling has great potential for improving cancer screening and diagnosis and understanding disease pathogenesis. PFAA profiles can also be used to determine various disease diagnoses from a single blood sample, which involves a relatively simple plasma assay and imposes a lower physical burden on subjects when compared to existing screening methods.",
author = "Yohei Miyagi and Masahiko Higashiyama and Akira Gochi and Makoto Akaike and Takashi Ishikawa and Takeshi Miura and Nobuhiro Saruki and Etsuro Bando and Hideki Kimura and Fumio Imamura and Masatoshi Moriyama and Ichiro Ikeda and Akihiko Chiba and Fumihiro Oshita and Akira Imaizumi and Hiroshi Yamamoto and Hiroshi Miyano and Katsuhisa Horimoto and Osamu Tochikubo and Toru Mitsushima and Minoru Yamakado and Naoyuki Okamoto",
year = "2011",
doi = "10.1371/journal.pone.0024143",
language = "English",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Plasma free amino acid profiling of five types of cancer patients and its application for early detection

AU - Miyagi, Yohei

AU - Higashiyama, Masahiko

AU - Gochi, Akira

AU - Akaike, Makoto

AU - Ishikawa, Takashi

AU - Miura, Takeshi

AU - Saruki, Nobuhiro

AU - Bando, Etsuro

AU - Kimura, Hideki

AU - Imamura, Fumio

AU - Moriyama, Masatoshi

AU - Ikeda, Ichiro

AU - Chiba, Akihiko

AU - Oshita, Fumihiro

AU - Imaizumi, Akira

AU - Yamamoto, Hiroshi

AU - Miyano, Hiroshi

AU - Horimoto, Katsuhisa

AU - Tochikubo, Osamu

AU - Mitsushima, Toru

AU - Yamakado, Minoru

AU - Okamoto, Naoyuki

PY - 2011

Y1 - 2011

N2 - Background: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection methods using blood samples. Among metabolites, profiling of plasma free amino acids (PFAAs) is a promising approach because PFAAs link all organ systems and have important roles in metabolism. Furthermore, PFAA profiles are known to be influenced by specific diseases, including cancers. Therefore, the purpose of the present study was to determine the characteristics of the PFAA profiles in cancer patients and the possibility of using this information for early detection. Methods and Findings: Plasma samples were collected from approximately 200 patients from multiple institutes, each diagnosed with one of the following five types of cancer: lung, gastric, colorectal, breast, or prostate cancer. Patients were compared to gender- and age- matched controls also used in this study. The PFAA levels were measured using high-performance liquid chromatography (HPLC)-electrospray ionization (ESI)-mass spectrometry (MS). Univariate analysis revealed significant differences in the PFAA profiles between the controls and the patients with any of the five types of cancer listed above, even those with asymptomatic early-stage disease. Furthermore, multivariate analysis clearly discriminated the cancer patients from the controls in terms of the area under the receiver-operator characteristics curve (AUC of ROC >0.75 for each cancer), regardless of cancer stage. Because this study was designed as case-control study, further investigations, including model construction and validation using cohorts with larger sample sizes, are necessary to determine the usefulness of PFAA profiling. Conclusions: These findings suggest that PFAA profiling has great potential for improving cancer screening and diagnosis and understanding disease pathogenesis. PFAA profiles can also be used to determine various disease diagnoses from a single blood sample, which involves a relatively simple plasma assay and imposes a lower physical burden on subjects when compared to existing screening methods.

AB - Background: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection methods using blood samples. Among metabolites, profiling of plasma free amino acids (PFAAs) is a promising approach because PFAAs link all organ systems and have important roles in metabolism. Furthermore, PFAA profiles are known to be influenced by specific diseases, including cancers. Therefore, the purpose of the present study was to determine the characteristics of the PFAA profiles in cancer patients and the possibility of using this information for early detection. Methods and Findings: Plasma samples were collected from approximately 200 patients from multiple institutes, each diagnosed with one of the following five types of cancer: lung, gastric, colorectal, breast, or prostate cancer. Patients were compared to gender- and age- matched controls also used in this study. The PFAA levels were measured using high-performance liquid chromatography (HPLC)-electrospray ionization (ESI)-mass spectrometry (MS). Univariate analysis revealed significant differences in the PFAA profiles between the controls and the patients with any of the five types of cancer listed above, even those with asymptomatic early-stage disease. Furthermore, multivariate analysis clearly discriminated the cancer patients from the controls in terms of the area under the receiver-operator characteristics curve (AUC of ROC >0.75 for each cancer), regardless of cancer stage. Because this study was designed as case-control study, further investigations, including model construction and validation using cohorts with larger sample sizes, are necessary to determine the usefulness of PFAA profiling. Conclusions: These findings suggest that PFAA profiling has great potential for improving cancer screening and diagnosis and understanding disease pathogenesis. PFAA profiles can also be used to determine various disease diagnoses from a single blood sample, which involves a relatively simple plasma assay and imposes a lower physical burden on subjects when compared to existing screening methods.

UR - http://www.scopus.com/inward/record.url?scp=80052526020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052526020&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0024143

DO - 10.1371/journal.pone.0024143

M3 - Article

C2 - 21915291

AN - SCOPUS:80052526020

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e24143

ER -